GSK Stock Recent News
GSK LATEST HEADLINES
Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Shares in GSK PLC (LSE:GSK, NYSE:GSK) opened higher following the US Food and Drug Administration's acceptance of gepotidacin for priority review as an oral treatment for uncomplicated urogenital gonorrhoea. The decision, based on positive phase III data from the EAGLE-1 trial, sets a target FDA decision date of December 2025.
British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral treatment of uncomplicated urogenital gonorrhoea.
GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.
GSK plc (NYSE:GSK ) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley - CEO & Director Julie Belita Brown - CFO & Executive Director Luke V. Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants James Daniel Gordon - JPMorgan Chase & Co, Research Division Kerry Ann Holford - Joh.
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.